Clinical Trial Update: A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update indicates Ascentage Pharma is evaluating APG-115 alone or with APG-2575 in relapsed/refractory T-cell prolymphocytic leukemia an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• APG-115 (APG-115)
• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | Phase 2 | Status: RECRUITING